Chong Kun Dang Pharmaceutical Corp. has disclosed 1,3,4-oxadiazole-containing compounds acting as histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of prion diseases, asthma, psoriasis, inflammatory bowel disease, autosomal dominant polycystic kidney, stroke, Charcot-Marie-Tooth disease and uveitis, among others.
Reglagene Inc. has prepared and tested compounds reported to be useful for the treatment of cancer, familial Mediterranean fever, gout and nail fungal infection.
Merck Sharp & Dohme LLC has identified compounds targeting α-synuclein (ASYN; NACP) acting as positron emission tomography agents reported to be useful for the diagnosis of Parkinson’s disease.
A patent from Nagasaki University discloses new protein aggregate degradation inducers reported to be useful for the treatment of neurodegenerative diseases.
Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have jointly developed new ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) and lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase; β-glucosidase) dual inhibitors reported to be useful for the treatment of mild cognitive impairment, among others.
Work at Innovstone Therapeutics Ltd. has led to the identification of new dihydrothienopyrimidine derivatives acting as phosphodiesterase PDE4B inhibitors.
A Hitgen Ltd. patent details aromatic-ring compounds acting as E3 ubiquitin-protein ligase (TRIM21) ligands reported to be useful for the treatment of cancer.
Zydus Lifesciences Ltd. has patented new compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors.
Tambo Inc. has described conjugates consisting of payloads covalently linked to trans-cyclooctene through a linker reported to be useful for the treatment of cancer.
RSS